Bionomics Limited

ABN 53 075 582 740

ASX ANNOUNCEMENT
18 March 2013

BIONOMICS CEO NAMED BIOSPECTRUM ASIA PERSON OF THE YEAR 2013

Bionomics Limited (ASX:BNO) (ADR: BMICY) CEO Dr Deborah Rathjen has been named BioSpectrum Asia-Pacific Person of the Year 2013. Dr Rathjen received the award at the fifth annual BioSpectrum Asia-Pacific Awards ceremony in Singapore.

BioSpectrum is an industry-leading life sciences periodical in the sector across the Asia-Pacific region. The award was judged by an independent jury assembled by BioSpectrum. Candidates were assessed against a range of criteria including performance of the company, key projects over the past year, global initiatives and stature as a leader and visionary. Previous winners of the award include Mesoblast CEO Dr Silviu Itescu, CSL CEO and Managing Director, Dr Brian McNamee and Green Cross President and CEO Mr Sup Il-Huh.

“Dr Rathjen has transformed Bionomics from a small gene therapy-based company to its current status as one of the most promising drug discovery organisations. Bionomics’ US$345 million Ironwood Pharmaceuticals license deal and purchase of US-based cancer stem cell company Eclipse Therapeutics are recent substantial achievements,” said BioSpectrum group editor Dr Narayanan Suresh.

“This award follows a particularly solid year of achievement in 2012 for Bionomics that included securing a major licensing agreement for the company’s anxiety drug candidate IW-2143. The deal with Ironwood Pharmaceuticals was identified by *FierceBiotech* as amongst the top 20 international deals of 2012,” said Dr Rathjen.

“The expansion of Bionomics’ global footprint with the acquisition of Eclipse Therapeutics and deep pipeline that now includes BNC375 for the treatment of cognitive disorders such as Alzheimer’s disease and BNC101 that targets cancer stem cells, has given Bionomics a platform for future growth.”

“I would like to acknowledge the entire Bionomics team who have worked hard to build and advance the drug discovery pipeline and who are behind the strong momentum that continues to drive us forward. We are excited about 2013 and look forward to reporting on another year of achievement.”

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited
Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 /
0418 160 425
drathjen@bionomics.com.au

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

The Trout Group
Lauren Glaser
+1 646 378 2972
lglaser@troutgroup.com

About Bionomics Limited

Bionomics (ASX: BNO) is an Australian based international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and autoimmune disorders, several of which are in or approaching clinical development stage. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours.

BNC105, which is undergoing Phase II clinical development for the treatment in a range of solid tumour types, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. BNC105 offers blockbuster potential if successfully developed. A clinical program is also underway for the treatment of anxiety disorders and depression based on IW-2143(BNC210), a novel compound which stimulates neurite outgrowth. IW-2143 is partnered with Ironwood Pharmaceuticals.

Bionomics' discovery and development activities are driven by its four proprietary technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX® , a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds.

www.bionomics.com.au

Factors Affecting Future Performance
This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105, IW-2143 (BNC210), BNC101 and BNC375, our acquisition of Eclipse Therapeutics and ability to develop products from their platform, its licensing deal with Ironwood Pharmaceuticals, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, Ironwood's decisions to continue or not continue development of IW-2143, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.